Company Overview - Evommune is developing next-generation therapies for chronic inflammation, which contributes to 3 out of 5 deaths worldwide[8] - The annual direct cost of chronic inflammation is at least $90 billion[9] - Evommune completed a $173 million IPO in November 2025 and has approximately $235 million in cash and investments as of September 30, 2025[115, 116] Clinical Programs - Evommune has two Phase 2 programs: EVO756 (oral MRGPRX2 antagonist) and EVO301 (long-acting IL-18 fusion protein)[15, 117] - EVO756 is being developed for chronic spontaneous urticaria (CSU) and atopic dermatitis (AD)[20, 117] - EVO301 is being developed for atopic dermatitis and ulcerative colitis[20, 117] - Three Phase 2 data readouts are expected in 2026: EVO756 in CSU (H1 2026), EVO756 in AD (H2 2026), and EVO301 in AD (H1 2026)[20, 117] EVO756 Clinical Data - In a Phase 2 trial in chronic inducible urticaria (CIndU), both 300 mg QD and 50 mg BID doses of EVO756 demonstrated robust clinical activity, with 30% of patients achieving a complete response after just 4 weeks[47, 49] - In the CIndU trial, at week 4, patients on 300 mg QD (N=10) saw a 14 point reduction and 50 mg BID patients (N=17) saw a 15 point reduction in Mean FricTest Score (0-4)[52] EVO756 Phase 2b Trials - A Phase 2b dose-ranging trial in CSU (N = 160) is underway, with topline data expected in H1 2026[72] - A Phase 2b dose-ranging trial in AD (N = 120) is underway, with topline data expected in H2 2026[80]

[music] The pandemic co it stopped the world. Over a period of three years 15 million people died and destroyed many families. But thank God it's over.Unfortunately now we are in a bigger part pandemic and that name of the pandemic is chronic inflammation. It's also called as a silent pandemic because most of us haven't heard about it. And sadly, it's also more devastating than the COVID pandemic.And here are the numbers so you get a perspective. COVID killed 5 million people a year. But chronic inflammatio ...

Core Insights - HCW Biologics Inc. is advancing its lead product candidate HCW11-040, a second-generation pembrolizumab-based immunotherapeutic, into late IND-enabling studies for the treatment of solid tumors [1][4] - The company has discovered a unique combination of cytokines that can expand Progenitor Exhausted T (TPEX) cells without causing a cytokine storm, which is a significant advancement in immunotherapy [2][3] Group 1: Product Development - HCW11-040 is a multi-functional fusion protein that combines pembrolizumab with interleukin (IL)-7, IL-15, and TGF-β receptor components, aimed at enhancing the immune response against cancer [2] - Preclinical studies indicate that HCW11-040 outperforms pembrolizumab monotherapy in immune-cell activation, tumor infiltration, and cytotoxicity against cancer cells [3] - The company plans to conduct high-expression manufacturing cell bank creation, chemistry manufacture control process development, and preclinical Good Laboratory Practice toxicology studies for HCW11-040 [4] Group 2: Company Overview - HCW Biologics is focused on developing novel immunotherapies to treat diseases associated with chronic inflammation, particularly age-related diseases [5] - The company utilizes its proprietary TRBC drug discovery platform to create a range of immunotherapeutics, including multi-functional immune cell stimulators and second-generation immune checkpoint inhibitors [6] - HCW Biologics has developed over 50 molecules using the TRBC platform, with ongoing preclinical evaluations for selected candidates based on promising data [6]

Core Viewpoint - Quantum BioPharma Ltd. has received approval for a Phase 2 clinical trial of FSD202, aimed at assessing its safety and efficacy in treating chronic widespread musculoskeletal nociplastic pain associated with idiopathic Mast Cell Activation Syndrome (MCAS) [1][4]. Group 1: Clinical Trial Details - The trial will enroll 60 patients with idiopathic MCAS, where participants will receive either FSD202 or a placebo twice daily for 56 days [1]. - The primary outcome will measure the decrease in average daily pain intensity from baseline to Day 28 [1]. - Secondary outcomes will also be evaluated during the trial [1]. Group 2: Drug Information - FSD202 contains ultra-micronized palmitoylethanolamide (PEA) and has potential applications for a variety of inflammatory diseases beyond MCAS [2]. - Chronic inflammatory diseases are a leading cause of death globally, with the World Health Organization identifying chronic disease as a significant health threat [2]. Group 3: Company Insights - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [4]. - The company retains a 20.11% ownership stake in Celly Nutrition, which is involved in the development of the OTC product unbuzzd™ [4]. - Quantum BioPharma has a royalty agreement with Celly Nutrition, receiving 7% of sales until total payments reach $250 million, after which the royalty rate will drop to 3% indefinitely [4].